title: Discovery of an orally available PAR-1 antagonist as a novel antiplatelet agent.
abstract: Antiplatelet therapy is a key treatment in atherothrombotic disease and platelet is activated via multiple pathways. Current agents do not interfere with all pathways including the protease-activated receptor-1 (PAR-1) pathway stimulated by thrombin. New antiplatelet agents targeting PAR-1 are aimed to reduce thrombosis ideally without increasing bleeding risk. This article provides a review of the new class of agents, PAR-1 antagonists.
authors.affiliation: Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Sinseongno 19, Yuseong-gu, Daejeon, 305-600, Korea. leesk@krict.re.kr
authors.forename: Sunkyung
authors.initials: S
authors.lastname: Lee
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy; D055808:Drug Discovery; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D013917:Thrombin / Q000378:metabolism
chemical_list: D010975:Platelet Aggregation Inhibitors; D013917:Thrombin